HC Wainwright Has Optimistic Outlook of CorMedix Q3 Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for CorMedix to $0.33 per share, up from a previous forecast of $0.23, maintaining a "Buy" rating and a target price of $17.00.
• CorMedix reported a quarterly earnings per share of $0.28, exceeding expectations, with a 4830.1% increase in revenue year-over-year, totaling $39.74 million.
• Despite the optimistic outlook, shares of CorMedix experienced a 4.4% decline, indicating fluctuating investor sentiment amid recent analyst rating changes.

CorMedix Inc (NASDAQ:CRMD - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings estimates for CorMedix in a research note issued to investors on Friday, August 8th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.33 per share for the quarter, up from their previous forecast of $0.23. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share.

CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.08. The business had revenue of $39.74 million for the quarter, compared to analyst estimates of $29.88 million. CorMedix had a net margin of 42.11% and a return on equity of 42.73%. The firm's revenue for the quarter was up 4830.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.25) earnings per share.

CRMD has been the topic of several other reports. D Boral Capital lowered shares of CorMedix from a "strong-buy" rating to a "hold" rating in a research report on Monday, June 30th. Wall Street Zen lowered shares of CorMedix from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Royal Bank Of Canada raised shares of CorMedix from an "outperform" rating to a "moderate buy" rating and upped their price target for the stock from $13.00 to $17.00 in a research report on Friday, June 20th. Needham & Company LLC upped their price target on shares of CorMedix from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, June 24th. Finally, D. Boral Capital lowered shares of CorMedix from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, CorMedix has a consensus rating of "Moderate Buy" and an average price target of $16.71.

CorMedix Stock Down 4.4%

Shares of CRMD stock opened at $10.33 on Monday. The company's fifty day simple moving average is $12.52 and its 200-day simple moving average is $10.79. The firm has a market cap of $771.13 million, a PE ratio of 13.77 and a beta of 1.71. CorMedix has a 12 month low of $3.61 and a 12 month high of $17.43.

Hedge Funds Weigh In On CorMedix

Institutional investors and hedge funds have recently modified their holdings of the stock. USA Financial Formulas acquired a new position in shares of CorMedix in the second quarter valued at $55,000. Allworth Financial LP increased its holdings in shares of CorMedix by 5,375.7% in the second quarter. Allworth Financial LP now owns 7,666 shares of the company's stock valued at $94,000 after purchasing an additional 7,526 shares during the last quarter. SBI Securities Co. Ltd. grew its stake in shares of CorMedix by 699.7% in the first quarter. SBI Securities Co. Ltd. now owns 8,685 shares of the company's stock valued at $54,000 after acquiring an additional 7,599 shares in the last quarter. ARS Wealth Advisors Group LLC acquired a new position in shares of CorMedix in the second quarter valued at about $123,000. Finally, Kapitalo Investimentos Ltda acquired a new position in shares of CorMedix in the second quarter valued at about $123,000. 34.18% of the stock is currently owned by institutional investors and hedge funds.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.